Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet or supplement regimen — particularly if you take anticoagulant medication or have an existing bone-related health condition.

Japan occupies an unusual position in the vitamin K2 research literature. It is the only country where a K2 compound is approved as a prescription medication — menatetrenone, a synthetic MK-4 form dosed at 45 mg per day, sold under the brand name Glakay for osteoporosis management. It is also the country where the food most responsible for building scientific interest in dietary K2 — natto — is a daily staple for a substantial portion of the population.

The prescription drug and the breakfast food use different K2 forms at doses separated by several orders of magnitude. What links them is a shared research question: does vitamin K2 status matter for bone quality and arterial health, and through what mechanisms?

What makes natto’s MK-7 content unusual

Vitamin K arrives in two main dietary families: K1 (phylloquinone, from leafy green vegetables) and K2 (menaquinones, from fermented foods and some animal products). Within the K2 family, individual menaquinone forms are distinguished by the length of their side chain — MK-4, MK-7, MK-8, MK-9, and beyond.

Natto stands apart from essentially every other common food in its MK-7 concentration. Soybeans fermented with Bacillus subtilis var. natto produce MK-7 biosynthetically as a fermentation byproduct; the concentration in finished natto runs roughly 850–1,000 µg per 100g depending on the fermentation batch. Aged cheeses, miso, and tempeh also contain menaquinones, but primarily in shorter MK-4 to MK-9 forms and at considerably lower concentrations. No other widely eaten food approaches natto’s MK-7 density.

Two properties make this MK-7 concentration pharmacologically relevant:

Serum half-life. MK-7 clears from human serum slowly — approximately three to four days, compared to a matter of hours for K1 and short-chain menaquinones like MK-4. This extended circulatory presence means a single natto serving sustains elevated K2 serum levels across several days. The sustained availability matters because the carboxylation reactions described below are ongoing processes, not single events.

Tissue distribution. MK-7’s extended half-life is accompanied by greater distribution to peripheral tissues — including bone and vascular smooth muscle — compared to K1. Both osteocalcin and Matrix GLA protein require K2 at tissue sites; circulating K1 reaches these tissues less effectively than the longer-chain menaquinones.

The osteocalcin pathway: how bone mineralization depends on K2

Osteoblasts — the bone-forming cells — synthesize osteocalcin, also referred to as bone Gla protein. Before osteocalcin can bind calcium and incorporate into the hydroxyapatite matrix that gives bone its structural density, it requires carboxylation: a γ-glutamyl carboxylase enzyme adds carboxyl groups to specific glutamate residues in the protein chain, and this reaction uses vitamin K2 as an obligate cofactor.

Carboxylated osteocalcin binds calcium within the hydroxyapatite lattice, contributing to bone mineralization. When K2 is functionally insufficient for this carboxylation reaction, undercarboxylated osteocalcin (ucOCN) accumulates — it circulates without being incorporated into bone matrix. The ratio of ucOCN to total osteocalcin has become a clinical research biomarker for K2 status in bone metabolism, and elevated ucOCN ratios have been correlated with lower bone mineral density in multiple cross-sectional studies of postmenopausal women and older adults.

The calibration that matters here: ucOCN ratio is a biomarker for a biological process, not a clinical outcome. Correlations between elevated ucOCN and lower bone mineral density in observational data are mechanistically coherent, but they do not establish that raising dietary K2 reduces fracture incidence. That causal inference requires long-term trials using fracture as an endpoint — and no published trial has yet delivered that at dietary-range K2 doses.

This K2-dependent bone pathway is mechanistically distinct from soy isoflavone effects on bone density (covered in detail in the fermented soy and isoflavone bone density article). Isoflavones act via estrogen receptor binding; osteocalcin carboxylation is estrogen-independent. Both mechanisms are present in natto, but they operate in parallel rather than through a shared pathway.

Matrix GLA protein and arterial calcification

A second K2-dependent carboxylation reaction operates in the vasculature — and it runs in a direction opposite to bone mineralization. Where vitamin K2 helps deposit calcium into bone via osteocalcin, it helps prevent calcium from depositing into arterial walls via Matrix GLA protein (MGP).

MGP is produced by vascular smooth muscle cells and chondrocytes. Its function is to inhibit calcium crystal nucleation in vessel walls — it acts as a local brake on the ectopic calcification process that characterizes arterial stiffening. Like osteocalcin, MGP requires K2-dependent carboxylation by γ-glutamyl carboxylase to be functionally active. When K2 is insufficient, uncarboxylated MGP (ucMGP) accumulates in vessel walls where it cannot suppress calcium deposition, and calcification proceeds.

Dephospho-uncarboxylated MGP (dp-ucMGP) has emerged as a circulating biomarker used in K2 research to estimate vascular K2 status — elevated dp-ucMGP is associated with increased cardiovascular calcification risk in several observational datasets.

The Rotterdam Study (Geleijnse et al., Journal of Nutrition, 2004) followed approximately 4,800 participants in the Netherlands and found that dietary K2 intake from fermented foods was associated with lower aortic calcification on X-ray, lower coronary heart disease incidence, and lower all-cause mortality over the follow-up period. Dietary K1 was not associated with the same cardiovascular outcomes in the same analysis — a finding interpreted as consistent with the tissue-distribution difference between K forms, since arterial smooth muscle accesses MK-7 more effectively than K1. This is an observational association in a Dutch population; mechanistic plausibility is high, but the study cannot resolve causality.

The MGP mechanism has given researchers a coherent biological rationale for pursuing K2 trials specifically targeting vascular calcification as an endpoint. RCT data on hard cardiovascular outcomes at dietary-range K2 doses remains limited.

What the cohort and trial evidence shows

Knapen et al. 2013 (Osteoporosis International): This is the most frequently cited controlled trial specific to MK-7. Healthy postmenopausal Dutch women received 180 µg/day of MK-7 supplementation or placebo for three years. The MK-7 group showed significantly slower decline in lumbar spine and femoral neck bone mineral density compared to placebo. The effect was more pronounced in participants over 55 with lower baseline K2 status. This is a modest-size, single-center RCT in a specific demographic — directionally informative but not a definitive fracture endpoint trial.

Japanese Population-based Osteoporosis Study (JPOS Study): The JPOS Study is a Japanese prospective cohort examining bone metabolism determinants across community-dwelling populations. Analyses from this cohort linking fermented soy intake — including natto-derived K2 — to bone mineral density outcomes have been broadly consistent with the Knapen trial direction. The observational design cannot isolate K2 from other components of natto or the fermented soy dietary pattern, including isoflavones.

Korean cohort data (K-POPS): Korean population-based osteoporosis prevention cohort analyses have produced directionally similar associations between dietary K2 intake and bone density markers, adding a replication signal in an East Asian population with some comparable dietary fermented soy patterns to the Japanese context. The Korea-based data is observational and carries the same confounding limitations as the Japanese cohort material.

Rotterdam Study (Geleijnse et al. 2004): As described above — the primary large observational dataset on K2 and cardiovascular calcification endpoints. The K2-specific cardiovascular signal in Rotterdam has not been replicated in an RCT with hard cardiovascular endpoints to date.

Taken together: the osteocalcin carboxylation mechanism is biochemically established; ucOCN correlates with bone mineral density in observational data; one RCT found a bone mineral density signal at 180 µg/day MK-7 over three years; Japanese and Korean cohort data are directionally consistent. The vascular calcification mechanism via MGP has strong preclinical support and observational backing in the Rotterdam Study. Neither axis has reached fracture incidence or cardiovascular event reduction in a controlled trial at dietary-range doses — that is the honest evidence calibration.

Getting MK-7 from natto or from a supplement

From the food itself: A standard 40–50g natto pack — the portion size sold in Japanese retail trays — contains approximately 400–500 µg of MK-7, well above the 180 µg/day used in the Knapen trial. Natto is rarely eaten on a clinical daily-dosing schedule outside Japan; most regular consumers eat it three to five times per week. The flavor profile — fermented, sticky, with a sharp ammonia edge — is a genuine acquisition barrier for most non-Japanese adults.

Frozen natto retains MK-7 through the freeze-thaw cycle because MK-7 is fat-soluble and not degraded by freezing. Azumaya Natto (Azuma Foods) and Okame-brand natto (Takanofoods) are the most consistently distributed frozen options in the US Japanese grocery supply chain. Mitsuwa Marketplace, Marukai, Nijiya, and certain H Mart locations with substantial Japanese import sections carry frozen natto with some consistency, though stock varies by location and season. Starting with hikiwari (chopped bean) format rather than whole-bean natto is a milder entry point — the texture is finer and the flavor slightly less intense.

From MK-7 supplements: For anyone who wants MK-7 outside the natto format, 100–180 µg/day is the dose range most aligned with the controlled trial data.

Amazon — NOW Foods Vitamin K2 MK-7: The NOW Foods MK-7 product at 180 µg directly mirrors the Knapen trial dose and is widely stocked in the US market. This is one of the more accessible MK-7 options at the evidence-referenced dose.

Amazon — Jarrow Formulas MK-7 menaquinone: Jarrow Formulas MK-7 is another established option in the category with available documentation on MK-7 standardization.

Amazon — natto extract K2 MK-7 capsules: Natto-derived MK-7 extracts in capsule form are available for those who prefer a food-source K2 over synthetically produced menaquinone. Verify the MK-7 dose on the label before purchasing.

One label-reading note worth flagging: MK-7 and MK-4 are distinct forms with different dosing contexts. The Japanese pharmaceutical menatetrenone trials that informed the drug approval used MK-4 at 45 mg per day — a pharmacological dose approximately 250 times higher than the dietary-range MK-7 doses used in the Knapen and most supplement trials. These are not interchangeable reference points. If the Knapen bone mineral density data is the evidence you are working from, confirm the label specifies MK-7 (menaquinone-7), not MK-4.

K2+D3 combination supplements are common, and the combination has mechanistic logic — both vitamins influence calcium metabolism and their pathways interact downstream. No RCT has compared K2+D3 versus K2 alone at dietary doses for bone or vascular outcomes, so the added clinical benefit of the combination over K2 alone is not established by trial data.

Who should consult a doctor before changing K2 intake

Warfarin and other vitamin K antagonist anticoagulants: This is the primary interaction concern, and it is not minor. Warfarin works by blocking the vitamin K-dependent synthesis of clotting factors; vitamin K2 from food or supplements directly counteracts that mechanism. Natto is specifically named in Japanese and international clinical cardiology references as a food that warfarin patients must avoid, precisely because MK-7’s three-to-four-day serum half-life and natto’s high content per serving create a sustained anticoagulation-reducing effect. Supplemental MK-7 at clinical doses carries the same concern. If you take warfarin, this is not an optional discussion with your prescribing physician.

Hypercalcemia or abnormal calcium metabolism: K2 facilitates calcium incorporation into bone and potentially away from vessel walls; conditions involving abnormal calcium handling warrant physician review before significantly changing K2 intake.

Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran): DOACs work via mechanisms that do not depend on vitamin K cycling, making them less directly susceptible to K2 interference than warfarin. Clinical interaction risk is considerably lower, but medical transparency when starting any new supplement remains appropriate.

A practical starting point

For someone who wants to increase MK-7 intake from food: add natto two to three times a week. The standard Japanese preparation — one tray over warm rice with a packet of Japanese mustard and a splash of naturally brewed soy sauce — is also the most practical entry point for flavor management. Hikiwari natto is milder in both texture and aroma than whole-bean, and it is an easier starting format for adults encountering natto for the first time.

For a supplement-based approach, 100–180 µg of MK-7 daily aligns with the dose range that the Knapen trial and related studies have examined. The food form and supplement form target the same carboxylation pathways and can be used in combination; natto portions contribute variably depending on frequency.

If bone density is an active clinical concern rather than background dietary interest, the appropriate prior step is baseline bone density screening (DEXA scan), followed by a clinical conversation covering both the K2 carboxylation evidence and the isoflavone-mediated evidence. Both mechanisms are present in fermented soy — the isoflavone pathway works via estrogen receptor binding (relevant especially for postmenopausal women) while K2’s bone effect operates independently of estrogen status. They are potentially additive as dietary priorities, and neither substitutes for clinical monitoring or medical management where osteoporosis is diagnosed.

---

Related: Fermented Soy and Bone Density: What the Isoflavone Evidence Shows | Nattokinase Capsules and Clot Research: What the Fibrin Dissolution Studies Show | Where to Buy Natto in the US: Frozen, Dried, and What Each Form Delivers